It is well appreciated that LDLR is suppressed during hyperlipidemia due to a well-described negative feedback loop and de-repression of hepatic LDLR levels results in enhanced cholesterol clearance, accounting for most of the benefit of statins and PCSK9 inhibitors. This evidence concerns the gene PCSK9 and hyperlipidemia.